SCHEMBL25972162

SCHEMBL25972162

CC(C)(C)OC(=O)Cc1cc(F)cc(F)c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 5/20 0.47
MTNR1B P49286 5/20 0.47
CYP4F2 P78329 1/20 0.41
CYP4A11 Q02928 1/20 0.41
HSP90AB1 P08238 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
RIPK1 Q13546 1/20 0.36
RIPK3 Q9Y572 1/20 0.36
IDO1 P14902 2/20 0.35
KCNQ3 O43525 1/20 0.34
KCNQ2 O43526 1/20 0.34
CTSS P25774 1/20 0.34
CTSK P43235 1/20 0.34
CES2 O00748 1/20 0.34
CES1 P23141 1/20 0.34
SLC6A3 Q01959 1/20 0.34
MAPK8 P45983 1/20 0.34
NR1D1 P20393 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15378035 0.89 MTNR1A (0.45) MTNR1AMTNR1BCYP4F2CYP4A11HSP90AB1
SCHEMBL17802775 0.86 MTNR1A (0.40) MTNR1AMTNR1BCYP4F2CYP4A11HSP90AB1
SCHEMBL15383526 0.85 MTNR1A (0.39) MTNR1AMTNR1BCYP4F2CYP4A11HSP90AB1
SCHEMBL25941174 0.85 MTNR1A (0.42) MTNR1AMTNR1BCYP4F2CYP4A11CTSS
SCHEMBL17999509 0.82 MTNR1A (0.42) MTNR1AMTNR1BCYP4F2CYP4A11RIPK1
SCHEMBL27394889 0.81 KDM4E (0.50) MTNR1AMTNR1BMEN1KMT2ACTSS
SCHEMBL27478049 0.79 CYP4F2 (0.46) CYP4F2CYP4A11HSP90AB1MEN1KMT2A
SCHEMBL1115348 0.79 HSP90AB1 (0.62) CYP4F2CYP4A11HSP90AB1MEN1KMT2A
SCHEMBL22774259 0.78 MTNR1A (0.42) MTNR1AMTNR1BHSP90AB1RIPK1RIPK3
SCHEMBL19974287 0.78 MTNR1A (0.42) MTNR1AMTNR1BHSP90AB1RIPK1RIPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718612-B2 Inhibitors of receptor interacting protein kinase I for the treatment of disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718612-B2 Inhibitors of receptor interacting protein kinase I for the treatment of disease RIPK1, RIPK2, RIPK4 MTNR1A 2091/4885MTNR1B 2672/4885CYP4F2 4829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.